Population pharmacokinetic modelling of aripiprazole and its active metabolite, dehydroaripiprazole, in psychiatric patients

British Journal of Clinical Pharmacology

Volumn 66, Issue 6, 2008, Pages 802-810

  Kim, Jung Ryul ^a   Seo, Hyo Bum ^a   Cho, Joo Youn ^a   Kang, Do Hyung ^a   Kim, Yong Ku ^b   Bahk, Won Myong ^c   Yu, Kyung Sang ^a   Shin, Sang Goo ^a   Kwon, Jun Soo ^a   Jang, In Jin ^a  

^a Seoul National University College of Medicine   (South Korea)

^b Korea University College of Medicine   (South Korea)

^c The Catholic University of Korea College of Medicine   (South Korea)

Author keywords

Aripiprazole; Cytochrome P450 2D6; Genetic polymorphism; Metabolite; Population pharmacokinetics

Indexed keywords

ARIPIPRAZOLE; CYTOCHROME P450; DEHYDROARIPIPRAZOLE; DRUG METABOLITE; UNCLASSIFIED DRUG;

ADULT; ALLELE; ARTICLE; CLINICAL TRIAL; COMPARTMENT MODEL; COMPUTER PROGRAM; CYP2D6 GENE; DISTRIBUTION VOLUME; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; FEMALE; GENE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MENTAL PATIENT; MULTICENTER STUDY; PHASE 4 CLINICAL TRIAL; PRIORITY JOURNAL;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; CYTOCHROME P-450 CYP2D6; DRUG INTERACTIONS; DRUG MONITORING; FEMALE; GENOTYPE; HUMANS; MALE; MENTAL DISORDERS; METABOLIC CLEARANCE RATE; MIDDLE AGED; MODELS, BIOLOGICAL; PIPERAZINES; POLYMORPHISM, GENETIC; QUINOLONES; YOUNG ADULT;

EID: 56549111520     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2008.03223.x     Document Type: Article

References (25)

1. Shapiro DA, Renock S, Arrington E, Chiodo LA, Liu LX, Sibley DR, Roth BL, Mailman R. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology 2003 28 : 1400 11.
2. Otsuka Pharmaceutical Co. Ltd. Aripiprazole [Prescribing information Available at http://www.fda.gov/cder/foi/label/2008/021436s021,021713s16, 021729s8,021866s8lbl.pdf (last accessed 30 October 2008).
3. Raggi MA, Mandrioli R, Sabbioni C, Pucci V. Atypical antipsychotics: pharmacokinetics, therapeutic drug monitoring and pharmacological interactions. Curr Med Chem 2004 11 : 279 96.
4. Mauri MC, Volonteri LS, Colasanti A, Fiorentini A, De Gaspari IF, Bareggi SR. Clinical pharmacokinetics of atypical antipsychotics: a critical review of the relationship between plasma concentrations and clinical response. Clin Pharmacokinet 2007 46 : 359 88.
5. Gareri P, De Fazio P, De Fazio S, Marigliano N, Ferreri Ibbadu G, De Sarro G. Adverse effects of atypical antipsychotics in the elderly: a review. Drugs Aging 2006 23 : 937 56.
6. Molden E, Lunde H, Lunder N, Refsum H. Pharmacokinetic variability of aripiprazole and the active metabolite dehydroaripiprazole in psychiatric patients. Ther Drug Monit 2006 28 : 744 9.
7. Kubo M, Koue T, Inaba A, Takeda H, Maune H, Fukuda T, Azuma J. Influence of itraconazole co-administration and CYP2D6 genotype on the pharmacokinetics of the new antipsychotic aripiprazole. Drug Metab Pharmacokinet 2005 20 : 55 64.
8. Hendset M, Hermann M, Lunde H, Refsum H, Molden E. Impact of the CYP2D6 genotype on steady-state serum concentrations of aripiprazole and dehydroaripiprazole. Eur J Clin Pharmacol 2007 63 : 1147 51.
9. Koch I, Weil R, Wolbold R, Brockmoller J, Hustert E, Burk O, Nuessler A, Neuhaus P, Eichelbaum M, Zanger U, Wojnowski L. Interindividual variability and tissue-specificity in the expression of cytochrome P450 3A mRNA. Drug Metab Dispos 2002 30 : 1108 14.
10. Huang W, Lin YS, McConn DJ II., Calamia JC, Totah RA, Isoherranen N, Glodowski M, Thummel KE. Evidence of significant contribution from CYP3A5 to hepatic drug metabolism. Drug Metab Dispos 2004 32 : 1434 45.
11. Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, Watkins PB, Daly A, Wrighton SA, Hall SD, Maurel P, Relling M, Brimer C, Yasuda K, Venkataramanan R, Strom S, Thummel K, Boguski MS, Schuetz E. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001 27 : 383 91.
12. Mallikaarjun S, Salazar DE, Bramer SL. Pharmacokinetics, tolerability, and safety of aripiprazole following multiple oral dosing in normal healthy volunteers. J Clin Pharmacol 2004 44 : 179 87.
13. Kubo M, Koue T, Maune H, Fukuda T, Azuma J. Pharmacokinetics of aripiprazole, a new antipsychotic, following oral dosing in healthy adult Japanese volunteers: influence of CYP2D6 polymorphism. Drug Metab Pharmacokinet 2007 22 : 358 66.
14. Citrome L, Josiassen R, Bark N, Salazar DE, Mallikaarjun S. Pharmacokinetics of aripiprazole and concomitant lithium and valproate. J Clin Pharmacol 2005 45 : 89 93.
15. Citrome L, Macher JP, Salazar DE, Mallikaarjun S, Boulton DW. Pharmacokinetics of aripiprazole and concomitant carbamazepine. J Clin Psychopharmacol 2007 27 : 279 83.
16. Gaedigk A, Gotschall RR, Forbes NS, Simon SD, Kearns GL, Leeder JS. Optimization of cytochrome P4502D6 (CYP2D6) phenotype assignment using a genotyping algorithm based on allele frequency data. Pharmacogenetics 1999 9 : 669 82.
17. Gaedigk A, Bradford LD, Alander SW, Leeder JS. CYP2D6*36 gene arrangements within the CYP2D6 locus: association of CYP2D6*36 with poor metabolizer status. Drug Metab Dispos 2006 34 : 563 9.
18. Zanger UM, Raimundo S, Eichelbaum M. Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Naunyn Schmiedebergs Arch Pharmacol 2004 369 : 23 37.
19. Boeckman A, Sheiner L, Beal S. NONMEM Users Guides. Icon Development Solutions, Ellicott City, MD, USA, 1989-1998.
20. Xuejun C, Ekaterina G, Suresh M. Population pharmacokinetic analysis of aripiprazole. X meeting of the Population Approach Group in Europe (Abstract 228), 2001. Available at http://www.page-meeting.org/?abstract=228 (last accessed 30 October 2008).
21. Mallikaarjun S, Ali MW, Salazar DE, Bramer SL. The effects of age and gender on the pharmacokinetics of aripiprazole. Clin Pharmacol Ther 2002 71 : TPII-90 (abstract).
22. Kitada M. Genetic polymorphism of cytochrome P450 enzymes in Asian populations: focus on CYP2D6. Int J Clin Pharmacol Res 2003 23 : 31 5.
23. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 1994 270 : 414 23.
24. Grunder G, Fellows C, Janouschek H, Veselinovic T, Boy C, Brocheler A, Kirschbaum KM, Hellmann S, Spreckelmeyer KM, Hiemke C, Rosch F, Schaefer WM, Vernaleken I. Brain and plasma pharmacokinetics of aripiprazole in patients with schizophrenia: an [18F]Fallypride PET study. Am J Psychiatry 2008 Apr 1 [Epub ahead of print F, Grunder G, Biziere K, Stephane M, Dogan AS, Dannals RF, Ravert H, Suri A, Bramer S, Wong DF. Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C]raclopride. Neuropsychopharmacology 2002 27 : 248 59.
25. Kirschbaum KM, Muller MJ, Malevani J, Mobascher A, Burchardt C, Piel M, Hiemke C. Serum levels of aripiprazole and dehydroaripiprazole, clinical response and side effects. World J Biol Psychiatry 2007 May 11 [Epub ahead of print]. 1 7.